Could a common heart drug boost immunotherapy against melanoma?

NCT ID NCT03384836

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial investigates whether adding propranolol, a beta-blocker typically used for heart conditions, can enhance the effects of the immunotherapy drug pembrolizumab in people with advanced melanoma that cannot be removed by surgery. The study includes two phases: first to find the safest dose of the combination, then to measure how well it shrinks tumors. Participants have stage IIIC or IV melanoma and have not received prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
propranolol hydrochloride and pembrolizumab
What this could lead to
If successful, this combination could improve response rates and survival for people with advanced melanoma.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. Adding propranolol could increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IIIC CUTANEOUS MELANOMA AJCC V7 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic Cancer Center

    Cleveland, Ohio, 44195, United States

  • Emory University Hospital/ Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Penn State Milton S. Hershy Medical Center Cancer Institute

    Hershey, Pennsylvania, 17033, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.